SWKH News and Press, SWK Holdings Corporation From 12/24/20

SWK Holdings' (SWKH) wholly-owned subsidiary, Enteris BioPharma received a second milestone payment of $2.5M from Cara Therapeutics (CARA) with regards the license agreement for Peptelligence oral formulation technology utilized in Oral KORSUVA.According to the contractual splits ag...

SWK Holdings' Subsidiary, Enteris BioPharma, Receives Second Milestone Payment from Cara Therapeutics Second milestone payment related to the development of Oral KORSUVA™ follows initial $2.5 million milestone payment received in October PR Newswire DALLAS ...

EyePoint Pharmaceuticals (EYPT) announces a royalty monetization agreement with SWK Holdings (SWKH) for royalties payable to EYPT under its license agreement with Alimera Sciences (ALIM) for ILUVIEN.EyePoint has received a one-time $16.5M payment from SWK and, in return, SWK is entitled to re...

Enteris BioPharma to Participate in Biotech Showcase Digital and BIO @ JPM During "J.P. Morgan Week 2021" BOONTON, N.J. , Dec. 17, 2020 /PRNewswire/ -- Enteris BioPharma, Inc. , a biotechnology company developing innovative drug products based on its proprietary del...

SWK Holdings (SWKH): Q3 GAAP EPS of $0.34 beats by $0.40.Revenue of $10.65M (+67.7% Y/Y) beats by $4.09M.Enteris BioPharma, a wholly-owned subsidiary of SWK Holdings, recognized $2.5M in milestone revenue under the license agreement with Cara Therapeutics.Closed $4.4M purchase of portfolio of...

SWK Holdings Corporation Announces Financial Results for Third Quarter 2020 Conference Call and Live Audio Webcast Scheduled for Monday, November 16, 2020, at 10:00 a.m. ET PR Newswire DALLAS, Nov. 13, 2020 DALLAS , Nov. 13, 2020 /PRNewswire/ -- ...

SWK Holdings Corporation to Participate in A.G.P.'s Virtual Healthcare Symposium PR Newswire DALLAS, Nov. 11, 2020 DALLAS , Nov. 11, 2020 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, today...

SWK Holdings' (SWKH) subsidiary, Enteris BioPharma, has received a milestone payment of $2.5M from Cara Therapeutics (CARA) related to the license agreement for Peptelligence oral formulation technology utilized in Oral KORSUVA, the oral formulation of CR845/difelikefalin.SWK is ent...

SWK Holdings' Subsidiary, Enteris BioPharma, Receives Milestone Payment from Cara Therapeutics First of multiple anticipated milestone payments related to the development of Oral KORSUVA™ PR Newswire DALLAS, Oct. 27, 2020 DALLAS , Oct. 27, 2020 /PR...

Financial Services Virtual Investor Conference Presentations Now Available for On-Demand Viewing PR Newswire NEW YORK, Sept. 28, 2020 NEW YORK , Sept. 28, 2020 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, t...